ImmunityBio has surged over 200% YTD, yet I see little fundamental justification for its current $10B enterprise value. Click here to read why IBRX is a Sell.

New implantable pancreatic cancer treatment honoured in the Problem Solver category at the Shaping Australia Awards University of Wollongong ...

Vanda Pharmaceuticals VNDA shares are up during Wednesday’s premarket session following the FDA’s approval of Bysanti, a new ...

Gross-to-net rebate reserve timing created quarterly net sales volatility, particularly in 2025 first and fourth quarters, ...

Overall, the Senate hearing was intense but constructive, with Means taking a conciliatory tone in lines of questioning on vaccines and more.

ImmunityBio (NASDAQ: IBRX) recently announced a partnership with Accord Healthcare to expand European access to ANKTIVA for bladder cancer patients across 33 countries. ANKTIVA achieved a 71% complete ...

Roughly one in three European founder-CEOs seriously considered quitting in 2025, driven by chronic stress and identity ...

(CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 ...

Study Confirms Safety of Using Theranica’s Nerivio REN Wearable for Treatment of Migraine Simultaneously with Contemporary Continuous Glucose Monitoring (CGM) Devices Published in the Journal of ...

European scale-ups are posting record growth after layoffs, but the employees who survived the cuts are experiencing chronic burnout, cognitive decline, and enforced silence — a hidden cost that the ...

New AI-Driven Planning Platform Designed to Unlock a New Class of Disease-Modifying Therapies for CNS DisordersMUNICH & REDWOOD CITY, Calif.--(BUSINESS WIRE)--#AI--Brainlab SE (Brainlab), a digital ...

Medical physicist Todd McNutt explains how Plan AI, an artificial intelligence-powered plan quality software solution, uses ...